ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.0500
+0.0300 (+1.49%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.0200
Open2.0300
Bid2.0300 x 0
Ask2.0700 x 0
Day's Range1.9900 - 2.1300
52 Week Range0.4800 - 7.8400
Volume140,475
Avg. Volume351,309
Market Cap76.619M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-1.4960
Earnings DateMar. 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Baystreet

    Stocks in play: Oncolytics Biotech Inc.

    Announced positive clinical data published in a peer-reviewed journal highlighting that the combination ...

  • CNW Group

    Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

    Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

  • Thomson Reuters StreetEvents

    Edited Transcript of ONC.TO earnings conference call or presentation 5-Mar-20 10:00pm GMT

    Q4 2019 Oncolytics Biotech Inc Earnings Call

  • CNW Group

    IIROC Trade Resumption - ONC

    TORONTO , March 24, 2020 /CNW/ - Trading resumes in: Company: Oncolytics Biotech Inc. TSX Symbol: ONC Resumption (ET): 02:26:07 PM IIROC can make a decision to impose a temporary suspension (halt) of trading ...

  • CNW Group

    IIROC Trading Halt - ONC

    IIROC Trading Halt - ONC

  • Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
    CNW Group

    Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

    SAN DIEGO, California and CALGARY, Alberta , March 24, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1. The Committee also approved an amendment of the study to reduce the dose of Tecentriq to be consistent with the currently approved breast cancer dose of 840mg. The study will continue to enroll patients and the Safety Committee will meet again for an additional pre-planned meeting.

  • Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
    CNW Group

    Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta, March 5, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY - News) (TSX:ONC.TO - News), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2019. "As we implemented our focused clinical development and investor relations strategies during 2019, our market valuation and trading volume experienced significant increases," said Kirk Look, Chief Financial Officer at Oncolytics. "During 2019, we successfully delivered on our strategy to engage pharma as we laid the groundwork for a catalyst rich 2020 and 2021," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

  • Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
    Zacks

    Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?

    During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

  • CNW Group

    Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

    SAN DIEGO and CALGARY, Alberta , Feb. 28, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday , March 5, 2020 following release of its fourth quarter and year end 2019 financial results. Overseas callers should contact investor relations for the toll-free dial information for their country. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.